Increasing evidences have shown that YBX3 is aberrantly upregulated in hepatocellular carcinoma [40], pancreatic cancer [61], colon cancer [62] and lung cancer [63]. This evidence concerns the gene YBX3 and familial pancreatic carcinoma.